Publication | Closed Access

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

Hematological MalignancyGemtuzumab OzogamicinCell Cycle-dependent KillingMedicineImmunologyEndocytic CapacityCell DeathImmune Checkpoint InhibitorAnti-cancer AgentCancer TreatmentImmunotherapyOncologyCell BiologyCancer ResearchTumor Biology